Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Page 1
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
Simões EAF, Madhi SA, Muller WJ, Atanasova V, Bosheva M, Cabañas F, Baca Cots M, Domachowske JB, Garcia-Garcia ML, Grantina I, Nguyen KA, Zar HJ, Berglind A, Cummings C, Griffin MP, Takas T, Yuan Y, Wählby Hamrén U, Leach A, Villafana T. Simões EAF, et al. Among authors: griffin mp. Lancet Child Adolesc Health. 2023 Mar;7(3):180-189. doi: 10.1016/S2352-4642(22)00321-2. Epub 2023 Jan 9. Lancet Child Adolesc Health. 2023. PMID: 36634694 Free PMC article.
BACKGROUND: In a phase 2b trial and the phase 3 MELODY trial, nirsevimab, an extended half-life, monoclonal antibody against respiratory syncytial virus (RSV), protected healthy infants born preterm or at full term against medically attended RSV lower respiratory tract inf …
BACKGROUND: In a phase 2b trial and the phase 3 MELODY trial, nirsevimab, an extended half-life, monoclonal antibody against respiratory syn …
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.
Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, Muller WJ, Zar HJ, Brooks D, Grenham A, Wählby Hamrén U, Mankad VS, Ren P, Takas T, Abram ME, Leach A, Griffin MP, Villafana T; MELODY Study Group. Hammitt LL, et al. Among authors: griffin mp. N Engl J Med. 2022 Mar 3;386(9):837-846. doi: 10.1056/NEJMoa2110275. N Engl J Med. 2022. PMID: 35235726 Clinical Trial.
The efficacy and safety of nirsevimab in healthy late-preterm and term infants are uncertain. METHODS: We randomly assigned, in a 2:1 ratio, infants who had been born at a gestational age of at least 35 weeks to receive a single intramuscular injection of nirsevimab or pla …
The efficacy and safety of nirsevimab in healthy late-preterm and term infants are uncertain. METHODS: We randomly assigned, in a 2:1 …
Microbial burden and viral exacerbations in a longitudinal multicenter COPD cohort.
Bouquet J, Tabor DE, Silver JS, Nair V, Tovchigrechko A, Griffin MP, Esser MT, Sellman BR, Jin H. Bouquet J, et al. Among authors: griffin mp. Respir Res. 2020 Mar 30;21(1):77. doi: 10.1186/s12931-020-01340-0. Respir Res. 2020. PMID: 32228581 Free PMC article.
Increasing evidence shows that the microbiota plays a role in disease progression and severity, but long-term and international multicenter assessment of the variations in viral and bacterial communities as drivers of exacerbations are lacking. ...
Increasing evidence shows that the microbiota plays a role in disease progression and severity, but long-term and international multi …
Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial.
O'Brien KL, Chandran A, Weatherholtz R, Jafri HS, Griffin MP, Bellamy T, Millar EV, Jensen KM, Harris BS, Reid R, Moulton LH, Losonsky GA, Karron RA, Santosham M; Respiratory Syncytial Virus (RSV) Prevention study group. O'Brien KL, et al. Among authors: griffin mp. Lancet Infect Dis. 2015 Dec;15(12):1398-408. doi: 10.1016/S1473-3099(15)00247-9. Epub 2015 Nov 4. Lancet Infect Dis. 2015. PMID: 26511956 Clinical Trial.
We aimed to assess the safety and efficacy of an anti-RSV monoclonal antibody (motavizumab) in healthy term (36 weeks' gestational age) infants for the prevention of medically attended RSV acute lower respiratory tract infections. ...The findings do not support a direct, g …
We aimed to assess the safety and efficacy of an anti-RSV monoclonal antibody (motavizumab) in healthy term (36 weeks' gestational ag …
Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness.
Ramilo O, Lagos R, Sáez-Llorens X, Suzich J, Wang CK, Jensen KM, Harris BS, Losonsky GA, Griffin MP; Motavizumab Study Group. Ramilo O, et al. Among authors: griffin mp. Pediatr Infect Dis J. 2014 Jul;33(7):703-9. doi: 10.1097/INF.0000000000000240. Pediatr Infect Dis J. 2014. PMID: 24356256 Clinical Trial.
BACKGROUND: This study was conducted to determine whether treatment with motavizumab, an anti-respiratory syncytial virus (RSV) monoclonal antibody, would decrease viral load and improve clinical outcomes in previously healthy term infants hospitalized with RSV lower respi …
BACKGROUND: This study was conducted to determine whether treatment with motavizumab, an anti-respiratory syncytial virus (RSV) monoclonal a …
Clinical screening and intervention in cases of partner violence.
Griffin MP, Kossn MP. Griffin MP, et al. Online J Issues Nurs. 2002;7(1):3. Online J Issues Nurs. 2002. PMID: 12044214
Partner violence is a long-term health risk factor that can potentially have far-reaching, negative consequences on both those abused and their loved ones. The term "partner" is used to define opposite and same sex couples who are in relationships on a continuum ran …
Partner violence is a long-term health risk factor that can potentially have far-reaching, negative consequences on both those abused …
Neurodevelopmental outcome in neonates after extracorporeal membrane oxygenation: cranial magnetic resonance imaging and ultrasonography correlation.
Griffin MP, Minifee PK, Landry SH, Allison PL, Swischuk LE, Zwischenberger JB. Griffin MP, et al. J Pediatr Surg. 1992 Jan;27(1):33-5. doi: 10.1016/0022-3468(92)90099-s. J Pediatr Surg. 1992. PMID: 1552440
After ECMO, the absence of intracranial hemorrhage, cerebral infarct, or cerebral atrophy on US or MRI usually correlates with normal short-term neurodevelopmental outcome....
After ECMO, the absence of intracranial hemorrhage, cerebral infarct, or cerebral atrophy on US or MRI usually correlates with normal short- …
Decreasing blood donor exposure in neonates on extracorporeal membrane oxygenation.
Minifee PK, Daeschner CW 3rd, Griffin MP, Allison PL, Zwischenberger JB. Minifee PK, et al. Among authors: griffin mp. J Pediatr Surg. 1990 Jan;25(1):38-42. doi: 10.1016/s0022-3468(05)80161-7. J Pediatr Surg. 1990. PMID: 2299546
Successful, widespread usage of ECMO in neonatal respiratory failure is placing increased numbers of surviving infants at risk for acute and long-term transfusion related problems. We assessed DE rates in 21 consecutive neonatal ECMO survivors. ...
Successful, widespread usage of ECMO in neonatal respiratory failure is placing increased numbers of surviving infants at risk for acute and …
Short- and long-term effects of cromolyn sodium on the airway reactivity of asthmatics.
Griffin MP, MacDonald N, McFadden ER Jr. Griffin MP, et al. J Allergy Clin Immunol. 1983 Mar;71(3):331-8. doi: 10.1016/0091-6749(83)90088-x. J Allergy Clin Immunol. 1983. PMID: 6402540 Clinical Trial.
After 2 wk of cromolyn, PD20VE rose significantly and stayed elevated during the course of the study. Neither the short- nor long-term administration of cromolyn had any effect on the responsiveness to methacholine. These results demonstrated that long-term therapy …
After 2 wk of cromolyn, PD20VE rose significantly and stayed elevated during the course of the study. Neither the short- nor long-term …